TG Therapeutics Initiates Phase 2 Trial for Briumvi
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 day ago
0mins
TG Therapeutics announced the initiation of a Phase 2 clinical trial evaluating Briumvi, in adults with treatment-resistant schizophrenia. The Phase 2 study is an open-label trial designed to evaluate the efficacy and safety of Briumvi in approximately 60 adults with schizophrenia who continue to experience significant symptoms despite receiving standard-of-care antipsychotic treatment.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TGTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TGTX
Wall Street analysts forecast TGTX stock price to fall
4 Analyst Rating
3 Buy
0 Hold
1 Sell
Moderate Buy
Current: 55.470
Low
15.00
Averages
43.50
High
60.00
Current: 55.470
Low
15.00
Averages
43.50
High
60.00
About TGTX
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
TG Therapeutics Q2 Earnings Outlook Focuses on Briumvi
- Briumvi Sales Expectations: TG Therapeutics' Briumvi treatment is the main driver of revenue growth, with analysts predicting that Q2 results will focus on whether Briumvi continues to exceed elevated expectations, as investors look for U.S. revenue to meet the $220 million guidance and Wall Street's estimate of around $229 million.
- New Study Initiation: Earlier this week, TG Therapeutics announced the start of a mid-stage study testing Briumvi in patients with treatment-resistant schizophrenia, aiming to enroll about 60 adults with significant symptoms despite standard antipsychotic treatment, with the goal of assessing meaningful symptom reduction after 12 weeks.
- Analyst Rating Changes: According to Koyfin data, seven of the nine analysts covering TGTX rate it Buy or higher, while Bank of America raised its price target from $17 to $20 but maintained an 'Underperform' rating, indicating a potential downside of 66% from the stock's last close.
- Market Sentiment Shift: On Stocktwits, retail sentiment around TGTX stock shifted from 'bearish' to 'neutral' over the past 24 hours, with low message volume; some users expressed hopes for a premium buyout, while others noted that the current biotech M&A climate may keep the stock within its current range.
See More
TG Therapeutics Initiates Phase 2 Trial for BRIUMVI in Treatment-Resistant Schizophrenia
- Trial Initiation: TG Therapeutics has announced the initiation of a Phase 2 clinical trial for BRIUMVI (ublituximab-xiiy), aimed at evaluating its efficacy and safety in approximately 60 adults with treatment-resistant schizophrenia, marking a strategic expansion into mental health.
- Study Design: This study is an open-label, single-arm, multicenter trial where participants will receive intravenous BRIUMVI while continuing standard antipsychotic therapy, with the primary endpoint being the proportion of participants achieving at least a 20% reduction in PANSS total score at Week 12, demonstrating rigorous clinical response criteria.
- Scientific Rationale: The rationale behind the study is supported by emerging evidence suggesting that immune dysfunction and neuroinflammation may play a role in the pathophysiology of schizophrenia in some patients, with BRIUMVI's B-cell depletion capability offering new avenues for exploration in this area.
- Market Need: Schizophrenia is a severe psychiatric disorder with many patients experiencing persistent symptoms despite existing treatments, and the success of BRIUMVI could address this unmet medical need, further expanding its application in mental health treatment.
See More
Analysis of XBI ETF Trading Dynamics
- 52-Week Price Range: The XBI ETF has a 52-week low of $82.04 and a high of $150.49, with the latest trade at $149.87, indicating strong investor interest and volatility near its peak, reflecting ongoing confidence in the biotech sector.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average allows investors to better assess XBI's price trends, enabling more precise investment strategies and enhancing the effectiveness of trading decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units', providing flexibility that allows ETFs to better accommodate market demand, thus increasing their attractiveness as investment vehicles.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows or outflows; inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
TG Therapeutics Reports Positive Results for Subcutaneous BRIUMVI
- Positive Clinical Results: TG Therapeutics reported that in a small study involving 11 patients with myasthenia gravis, most experienced significant improvements in daily symptoms after six months of treatment with the new subcutaneous BRIUMVI, indicating its efficacy and safety profile.
- Sales Forecast Increase: The company reported approximately $205 million in global revenue for Q1 2026 and raised its full-year sales forecast to about $925 million, reflecting strong market performance and growth potential for BRIUMVI.
- Investor Sentiment Shift: Despite a 2% increase in TG Therapeutics' stock price on Wednesday, retail sentiment shifted from 'extremely bullish' to 'bullish', indicating cautious optimism among investors regarding future catalysts and stock price movements.
- Analyst Ratings Optimistic: Among the nine analysts covering TGTX, seven rated it 'Buy' or higher, with a 12-month average price target of $48, demonstrating confidence in the company's future growth prospects.
See More
TG Therapeutics Q2 Earnings Outlook Focuses on Briumvi
- Briumvi Sales Expectations: TG Therapeutics' Briumvi treatment is the main driver of revenue growth, with analysts predicting that Q2 results will focus on whether Briumvi continues to exceed elevated expectations, as investors look for U.S. revenue to meet the $220 million guidance and Wall Street's estimate of around $229 million.
- New Study Initiation: Earlier this week, TG Therapeutics announced the start of a mid-stage study testing Briumvi in patients with treatment-resistant schizophrenia, aiming to enroll about 60 adults with significant symptoms despite standard antipsychotic treatment, with the goal of assessing meaningful symptom reduction after 12 weeks.
- Analyst Rating Changes: According to Koyfin data, seven of the nine analysts covering TGTX rate it Buy or higher, while Bank of America raised its price target from $17 to $20 but maintained an 'Underperform' rating, indicating a potential downside of 66% from the stock's last close.
- Market Sentiment Shift: On Stocktwits, retail sentiment around TGTX stock shifted from 'bearish' to 'neutral' over the past 24 hours, with low message volume; some users expressed hopes for a premium buyout, while others noted that the current biotech M&A climate may keep the stock within its current range.
See More
TG Therapeutics Initiates Phase 2 Trial for BRIUMVI in Treatment-Resistant Schizophrenia
- Trial Initiation: TG Therapeutics has announced the initiation of a Phase 2 clinical trial for BRIUMVI (ublituximab-xiiy), aimed at evaluating its efficacy and safety in approximately 60 adults with treatment-resistant schizophrenia, marking a strategic expansion into mental health.
- Study Design: This study is an open-label, single-arm, multicenter trial where participants will receive intravenous BRIUMVI while continuing standard antipsychotic therapy, with the primary endpoint being the proportion of participants achieving at least a 20% reduction in PANSS total score at Week 12, demonstrating rigorous clinical response criteria.
- Scientific Rationale: The rationale behind the study is supported by emerging evidence suggesting that immune dysfunction and neuroinflammation may play a role in the pathophysiology of schizophrenia in some patients, with BRIUMVI's B-cell depletion capability offering new avenues for exploration in this area.
- Market Need: Schizophrenia is a severe psychiatric disorder with many patients experiencing persistent symptoms despite existing treatments, and the success of BRIUMVI could address this unmet medical need, further expanding its application in mental health treatment.
See More
Analysis of XBI ETF Trading Dynamics
- 52-Week Price Range: The XBI ETF has a 52-week low of $82.04 and a high of $150.49, with the latest trade at $149.87, indicating strong investor interest and volatility near its peak, reflecting ongoing confidence in the biotech sector.
- Technical Analysis Tool: Comparing the current share price to the 200-day moving average allows investors to better assess XBI's price trends, enabling more precise investment strategies and enhancing the effectiveness of trading decisions.
- ETF Unit Trading Mechanism: ETFs trade like stocks, where investors buy and sell 'units', providing flexibility that allows ETFs to better accommodate market demand, thus increasing their attractiveness as investment vehicles.
- Inflows and Outflows Monitoring: Weekly monitoring of changes in shares outstanding helps identify significant inflows or outflows; inflows necessitate purchasing underlying assets, while outflows may lead to selling, impacting the performance of individual stocks within the ETF.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS
- Drug Development Progress: Quantum BioPharma is advancing Lucid-MS, a novel drug candidate targeting multiple sclerosis by directly protecting the myelin sheath, with plans to enter phase 2 clinical trials that could transform current treatment paradigms.
- Significant Market Demand: The global market for MS therapeutics is projected to reach $27.4 billion in 2024 and grow to $38.62 billion by 2030, highlighting the urgent need for effective treatments, with Quantum BioPharma's innovative drug poised to address this gap.
- Successful Clinical Trials: The phase 1 clinical trial for Lucid-MS has been successfully completed, demonstrating a favorable safety profile and good tolerability, laying the groundwork for subsequent patient trials that could offer unprecedented potential for restoring lost functions.
- Collaborative Research Prospects: Quantum BioPharma is collaborating with Massachusetts General Hospital to utilize advanced imaging techniques to assess Lucid-MS's effectiveness, which could provide direct evidence of the drug's clinical impact and further accelerate its path to market.
See More
Quantum BioPharma Advances Novel MS Drug Candidate Lucid-MS into Phase 2 Trials
- Drug Development Progress: Quantum BioPharma's Lucid-MS is advancing into Phase 2 clinical trials, aiming to directly target the myelin sheath in multiple sclerosis (MS) patients, potentially filling a significant gap in current treatments and improving patient quality of life.
- Significant Market Potential: The global market for MS therapeutics was valued at approximately $27.4 billion in 2024 and is projected to reach $38.62 billion by 2030, highlighting the urgent need for effective therapies, with Quantum BioPharma's innovative drug poised to capture a substantial share.
- Successful Clinical Trials: Lucid-MS demonstrated a favorable safety and tolerability profile in Phase 1 trials, successfully completing dosing among healthy volunteers, laying the groundwork for subsequent patient trials, and offering new hope for MS patients if results are positive.
- Strong Scientific Team: Quantum BioPharma boasts a top-tier scientific team, including experts with extensive experience in medicinal chemistry and neurology, ensuring a rigorous development process for Lucid-MS, which aims to be the first treatment to directly protect the myelin sheath.
See More
TG Therapeutics Reports Positive Results for Subcutaneous BRIUMVI
- Positive Clinical Results: TG Therapeutics reported that in a small study involving 11 patients with myasthenia gravis, most experienced significant improvements in daily symptoms after six months of treatment with the new subcutaneous BRIUMVI, indicating its efficacy and safety profile.
- Sales Forecast Increase: The company reported approximately $205 million in global revenue for Q1 2026 and raised its full-year sales forecast to about $925 million, reflecting strong market performance and growth potential for BRIUMVI.
- Investor Sentiment Shift: Despite a 2% increase in TG Therapeutics' stock price on Wednesday, retail sentiment shifted from 'extremely bullish' to 'bullish', indicating cautious optimism among investors regarding future catalysts and stock price movements.
- Analyst Ratings Optimistic: Among the nine analysts covering TGTX, seven rated it 'Buy' or higher, with a 12-month average price target of $48, demonstrating confidence in the company's future growth prospects.
See More
